Amgen Stock Forecast, Price & News

Amgen (NASDAQ:AMGN) Frequently Asked Questions

Is Amgen a buy right now?

19 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amgen in the last twelve months. There are currently 2 sell ratings, 11 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Amgen stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMGN, but not buy additional shares or sell existing shares.
View analyst ratings for Amgen or view top-rated stocks.

How has Amgen's stock been impacted by COVID-19?

Amgen's stock was trading at $198.65 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AMGN shares have increased by 17.7% and is now trading at $233.83.
View which stocks have been most impacted by COVID-19.

When is Amgen's next earnings date?

Amgen is scheduled to release its next quarterly earnings announcement on Tuesday, February 1st 2022.
View our earnings forecast for Amgen.

How were Amgen's earnings last quarter?

Amgen Inc. (NASDAQ:AMGN) announced its quarterly earnings results on Tuesday, November, 2nd. The medical research company reported $4.67 earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of $4.22 by $0.45. The medical research company earned $6.71 billion during the quarter, compared to analysts' expectations of $6.70 billion. Amgen had a net margin of 21.77% and a trailing twelve-month return on equity of 108.67%. During the same period in the prior year, the company posted $4.37 EPS.
View Amgen's earnings history.

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Friday, December 3rd. Shareholders of record on Tuesday, February 15th will be given a dividend of $1.94 per share on Tuesday, March 8th. This represents a $7.76 dividend on an annualized basis and a dividend yield of 3.32%. The ex-dividend date is Monday, February 14th. This is a positive change from Amgen's previous quarterly dividend of $1.76.
View Amgen's dividend history.

Is Amgen a good dividend stock?

Amgen pays an annual dividend of $7.04 per share and currently has a dividend yield of 2.99%. Amgen has been increasing its dividend for 11 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio of Amgen is 72.50%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, Amgen will have a dividend payout ratio of 39.15% next year. This indicates that Amgen will be able to sustain or increase its dividend.
View Amgen's dividend history.

What guidance has Amgen issued on next quarter's earnings?

Amgen issued an update on its FY 2021 earnings guidance on Tuesday, November, 9th. The company provided EPS guidance of $16.500-$17.100 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $16.430. The company issued revenue guidance of $25.80 billion-$26.20 billion, compared to the consensus revenue estimate of $26.01 billion.

What price target have analysts set for AMGN?

19 Wall Street analysts have issued twelve-month target prices for Amgen's stock. Their forecasts range from $185.00 to $295.00. On average, they expect Amgen's stock price to reach $232.24 in the next year. This suggests that the stock has a possible downside of 0.7%.
View analysts' price targets for Amgen or view top-rated stocks among Wall Street analysts.

Who are Amgen's key executives?

Amgen's management team includes the following people:

• Robert A. Bradway, Chairman, President & Chief Executive Officer
• Esteban Santos, Executive Vice President-Operations
• Peter H. Griffith, Chief Financial Officer & Executive Vice President
• Mike Zahigian, Chief Information Officer & Senior Vice President
• David M. Reese, Executive Vice President-Research & Development

What is Robert A. Bradway's approval rating as Amgen's CEO?

806 employees have rated Amgen CEO Robert A. Bradway on Glassdoor.com. Robert A. Bradway has an approval rating of 91% among Amgen's employees. This puts Robert A. Bradway in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amgen's key competitors?

Some companies that are related to Amgen include Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Seagen (SGEN), Alnylam Pharmaceuticals (ALNY), Incyte (INCY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), United Therapeutics (UTHR), Novavax (NVAX), Neurocrine Biosciences (NBIX), Arena Pharmaceuticals (ARNA) and Exelixis (EXEL).
View all of AMGN's competitors.

What other stocks do shareholders of Amgen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amgen investors own include Johnson & Johnson (JNJ), NVIDIA (NVDA), Intel (INTC), Cisco Systems (CSCO), Pfizer (PFE), AbbVie (ABBV), Walt Disney (DIS), AT&T (T), Alibaba Group (BABA) and Home Depot (HD).

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

Who are Amgen's major shareholders?

Amgen's stock is owned by a variety of retail and institutional investors. Top institutional investors include Coho Partners Ltd. (0.13%), Cullinan Associates Inc. (0.04%), Royal London Asset Management Ltd. (0.03%), Gateway Investment Advisers LLC (0.03%), DNB Asset Management AS (0.03%) and Absher Wealth Management LLC (0.02%). Company insiders that own Amgen stock include David Piacquad, Jonathan P Graham, Nancy A Grygiel, Nancy A Grygiel, R Sanders Williams, Ronald D Sugar and Ronald D Sugar.
View institutional ownership trends for Amgen.

Which institutional investors are selling Amgen stock?

AMGN stock was sold by a variety of institutional investors in the last quarter, including M&G Investment Management Ltd., Coho Partners Ltd., Beacon Financial Group, Arlington Financial Advisors LLC, Canton Hathaway LLC, State of Alaska Department of Revenue, Royal London Asset Management Ltd., and Gateway Investment Advisers LLC. Company insiders that have sold Amgen company stock in the last year include Jonathan P Graham, Nancy A Grygiel, R Sanders Williams, and Ronald D Sugar.
View insider buying and selling activity for Amgen or view top insider-selling stocks.

Which institutional investors are buying Amgen stock?

AMGN stock was acquired by a variety of institutional investors in the last quarter, including Stonnington Group LLC, Absher Wealth Management LLC, Brookstone Capital Management, Osher Van de Voorde Investment Management, Farmers & Merchants Investments Inc., Kempner Capital Management Inc., Abundance Wealth Counselors, and Virginia Wealth Management Group Inc..
View insider buying and selling activity for Amgen or or view top insider-buying stocks.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $233.83.

How much money does Amgen make?

Amgen has a market capitalization of $131.71 billion and generates $25.42 billion in revenue each year. The medical research company earns $7.26 billion in net income (profit) each year or $9.71 on an earnings per share basis.

How many employees does Amgen have?

Amgen employs 24,300 workers across the globe.

Does Amgen have any subsidiaries?

The following companies are subsidiares of Amgen: Abgenix, Alantos Pharmaceuticals, Amgen (Europe) GmbH, Amgen Fremont Inc., Amgen Global Finance B.V., Amgen GmbH Germany, Amgen Ilaç Ticaret Limited Şirketi, Amgen Manufacturing Limited, Amgen Research (Munich) GmbH, Amgen Rockville Inc., Amgen S.A.S., Amgen SF LLC, Amgen Singapore Manufacturing Pte. Ltd., Amgen Technology (Ireland) Unlimited Company, Amgen Technology Limited, Amgen USA Inc., Amgen Worldwide Holdings B.V., Avidia, Bergamo, BioVex, BioVex Inc., Catherex, DeCODE Genetics, Dezima Pharma, Filgrastim and Pegfilgrastim, Five Prime Therapeutics, Gensenta İlaç Sanayi ve Ticaret Anonim Şirketi, Ilypsa, Immunex, Immunex Corporation, Immunex Rhode Island Corporation, KAI Pharmaceuticals, Kinetix Pharmaceuticals, Laboratorio Quimico Farmaceutico Bergamo, MN Pharmaceuticals, Micromet, Nuevolution, Onyx Pharmaceuticals, Onyx Pharmaceuticals Inc., Onyx Therapeutics Inc., Otezla, Rodeo Therapeutics, Synergen, and Tularik.

When was Amgen founded?

Amgen was founded in 1980.

What is Amgen's official website?

The official website for Amgen is www.amgen.com.

Where are Amgen's headquarters?

Amgen is headquartered at ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at (805) 447-1000, via email at [email protected], or via fax at 805-447-1010.